Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
OFIX's Cash-to-Debt is ranked higher than
97% of the 335 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. OFIX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OFIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 5.19 Max: No Debt
Current: No Debt
Equity-to-Asset 0.75
OFIX's Equity-to-Asset is ranked higher than
69% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. OFIX: 0.75 )
Ranked among companies with meaningful Equity-to-Asset only.
OFIX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.7 Max: 0.85
Current: 0.75
0.36
0.85
Interest Coverage 132.24
OFIX's Interest Coverage is ranked higher than
54% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: 73.23 vs. OFIX: 132.24 )
Ranked among companies with meaningful Interest Coverage only.
OFIX' s Interest Coverage Range Over the Past 10 Years
Min: 0.68  Med: 6.72 Max: No Debt
Current: 132.24
Piotroski F-Score: 7
Altman Z-Score: 7.70
Beneish M-Score: -2.99
WACC vs ROIC
4.25%
-6.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 4.82
OFIX's Operating Margin % is ranked higher than
56% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. OFIX: 4.82 )
Ranked among companies with meaningful Operating Margin % only.
OFIX' s Operating Margin % Range Over the Past 10 Years
Min: -49.44  Med: 4.7 Max: 17.01
Current: 4.82
-49.44
17.01
Net Margin % -0.82
OFIX's Net Margin % is ranked lower than
56% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. OFIX: -0.82 )
Ranked among companies with meaningful Net Margin % only.
OFIX' s Net Margin % Range Over the Past 10 Years
Min: -43.98  Med: 0.02 Max: 9.73
Current: -0.82
-43.98
9.73
ROE % -1.26
OFIX's ROE % is ranked lower than
57% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. OFIX: -1.26 )
Ranked among companies with meaningful ROE % only.
OFIX' s ROE % Range Over the Past 10 Years
Min: -71.87  Med: 0.08 Max: 16.37
Current: -1.26
-71.87
16.37
ROA % -0.92
OFIX's ROA % is ranked lower than
53% of the 336 Companies
in the Global Medical Devices industry.

( Industry Median: 0.33 vs. OFIX: -0.92 )
Ranked among companies with meaningful ROA % only.
OFIX' s ROA % Range Over the Past 10 Years
Min: -31.59  Med: 0.04 Max: 7.45
Current: -0.92
-31.59
7.45
ROC (Joel Greenblatt) % 16.66
OFIX's ROC (Joel Greenblatt) % is ranked higher than
65% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.51 vs. OFIX: 16.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OFIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -121.91  Med: 13.27 Max: 27.87
Current: 16.66
-121.91
27.87
3-Year Revenue Growth Rate 1.40
OFIX's 3-Year Revenue Growth Rate is ranked lower than
62% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. OFIX: 1.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OFIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.5  Med: 13.7 Max: 28.7
Current: 1.4
-10.5
28.7
3-Year EBITDA Growth Rate 54.00
OFIX's 3-Year EBITDA Growth Rate is ranked higher than
90% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. OFIX: 54.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OFIX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.3 Max: 63.2
Current: 54
0
63.2
GuruFocus has detected 4 Warning Signs with Orthofix International NV $OFIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OFIX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113 
Compare:OTCPK:MZRTF, OTCPK:SBMAF, NAS:XENT, NAS:VASC, NAS:CSII, NAS:KTWO, NYSE:CRY, NAS:GNMK, OTCPK:NMRD, NAS:BABY, NAS:AXGN, NAS:TCMD, NAS:EXAC, NYSE:IVC, NAS:ELOS, NAS:ARAY, NAS:VRAY, AMEX:CVRS, NYSE:ITGR, NAS:CUTR » details
Traded in other countries:OFX.Germany,
Headquarter Location:
Orthofix International NV is a diversified medical device company. The Company is engaged in developing and delivering repair and regenerative solutions to the spine and orthopedic markets.

Orthofix International NV was formed on October 19, 1987 under the laws of the Netherlands Antilles. The Company is a diversified, medical device company engaged in developing and delivering repair and regenerative solutions to the spine and orthopedic markets. Its products are designed to address the lifelong bone-and-joint health needs of patients of all ages, helping them achieve a more active and mobile lifestyle. The Company designs, develops, manufactures, markets and distributes medical devices used mainly by musculoskeletal medical specialists for spine and orthopedic applications. Its main products are spinal implant products human cellular and tissue based products ('HCT/P products') used in surgical procedures, non-invasive regenerative stimulation products used to enhance bone growth and the success rate of spinal fusions and to treat non-union fractures, and external and internal fixation devices used in fracture repair, limb lengthening and bone reconstruction. The Company has administrative and training facilities in the United States, Brazil, the United Kingdom, France, Germany, Puerto Rico and Italy and manufacturing facilities in the U.S. and Italy. The Company directly distributes its products in the U.S., the United Kingdom, Italy, Germany, France, Belgium, Brazil, Australia, and Puerto Rico. The Company manages its business by its four strategic business units (SBUs), which are comprised of BioStim, Biologics, Extremity Fixation, Spine Fixation. The BioStim SBU manufactures, distributes, and provides support services for a portfolio of devices for enhancing bone fusion that utilize the Company's patented pulsed electromagnetic (PEMF) technology. These Food and Drug Administration-approved Class 3 medical devices are indicated as an adjunctive treatment to enhance fusion success in cervical and lumbar spine fusion as well as a therapeutic treatment for non-healing fractures outside of the spine. The Biologics SBU provides a portfolio of regenerative products that allow physicians to successfully treat various spinal and orthopedic conditions. This SBU specializes in the marketing of the Company's regeneration tissue forms. Biologics distributes its tissues through a network of distributors, sales, representatives and affiliates to market to hospitals, doctors, and other healthcare providers, mainly in the U.S. The Company's partnership with MTF allows it to exclusively market its Trinity Evolution and Trinity Elitetissue forms for musculoskeletal defects to enhance bone fusion. The Extremity Fixation SBU offers products that allow physicians to successfully treat various orthopedic conditions unrelated to the spine. This SBU specializes in the design, development, and marketing of the Company's orthopedic products used in fracture repair, deformity correction and bone reconstruction. Extremity Fixation distributes its products through a network of distributors, sales representatives, and affiliates. The Spine

Ratios

vs
industry
vs
history
Forward PE Ratio 30.40
OFIX's Forward PE Ratio is ranked lower than
59% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. OFIX: 30.40 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 3.13
OFIX's PB Ratio is ranked lower than
52% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. OFIX: 3.13 )
Ranked among companies with meaningful PB Ratio only.
OFIX' s PB Ratio Range Over the Past 10 Years
Min: 0.77  Med: 2.04 Max: 3.32
Current: 3.13
0.77
3.32
PS Ratio 2.03
OFIX's PS Ratio is ranked higher than
64% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.36 vs. OFIX: 2.03 )
Ranked among companies with meaningful PS Ratio only.
OFIX' s PS Ratio Range Over the Past 10 Years
Min: 0.31  Med: 1.55 Max: 2.32
Current: 2.03
0.31
2.32
Price-to-Free-Cash-Flow 30.51
OFIX's Price-to-Free-Cash-Flow is ranked higher than
52% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 32.05 vs. OFIX: 30.51 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
OFIX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.39  Med: 21.8 Max: 633.66
Current: 30.51
7.39
633.66
Price-to-Operating-Cash-Flow 19.35
OFIX's Price-to-Operating-Cash-Flow is ranked higher than
53% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 20.50 vs. OFIX: 19.35 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
OFIX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.73  Med: 13.2 Max: 271.03
Current: 19.35
5.73
271.03
EV-to-EBIT 39.70
OFIX's EV-to-EBIT is ranked lower than
73% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 24.85 vs. OFIX: 39.70 )
Ranked among companies with meaningful EV-to-EBIT only.
OFIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.7  Med: 20.8 Max: 272.1
Current: 39.7
-37.7
272.1
EV-to-EBITDA 31.66
OFIX's EV-to-EBITDA is ranked lower than
76% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 18.30 vs. OFIX: 31.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
OFIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -144.1  Med: 16.75 Max: 769.5
Current: 31.66
-144.1
769.5
Current Ratio 2.97
OFIX's Current Ratio is ranked higher than
56% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. OFIX: 2.97 )
Ranked among companies with meaningful Current Ratio only.
OFIX' s Current Ratio Range Over the Past 10 Years
Min: 1.56  Med: 3.43 Max: 5.24
Current: 2.97
1.56
5.24
Quick Ratio 1.92
OFIX's Quick Ratio is ranked higher than
50% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. OFIX: 1.92 )
Ranked among companies with meaningful Quick Ratio only.
OFIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 2.57 Max: 4.2
Current: 1.92
1.13
4.2
Days Inventory 261.05
OFIX's Days Inventory is ranked lower than
80% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 131.96 vs. OFIX: 261.05 )
Ranked among companies with meaningful Days Inventory only.
OFIX' s Days Inventory Range Over the Past 10 Years
Min: 222.27  Med: 246.29 Max: 336.86
Current: 261.05
222.27
336.86
Days Sales Outstanding 52.43
OFIX's Days Sales Outstanding is ranked higher than
75% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. OFIX: 52.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
OFIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.53  Med: 79.42 Max: 105.88
Current: 52.43
51.53
105.88
Days Payable 68.44
OFIX's Days Payable is ranked higher than
57% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 55.39 vs. OFIX: 68.44 )
Ranked among companies with meaningful Days Payable only.
OFIX' s Days Payable Range Over the Past 10 Years
Min: 48.79  Med: 69.08 Max: 81.8
Current: 68.44
48.79
81.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.50
OFIX's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. OFIX: 0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OFIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.6  Med: -1.7 Max: 1.2
Current: 0.5
-8.6
1.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 8.41
OFIX's Price-to-Net-Current-Asset-Value is ranked lower than
58% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 6.67 vs. OFIX: 8.41 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OFIX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.2  Med: 5.21 Max: 235
Current: 8.41
2.2
235
Price-to-Tangible-Book 4.07
OFIX's Price-to-Tangible-Book is ranked lower than
51% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 3.91 vs. OFIX: 4.07 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OFIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.48  Med: 4.21 Max: 110.32
Current: 4.07
1.48
110.32
Price-to-Intrinsic-Value-Projected-FCF 2.07
OFIX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
60% of the 143 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. OFIX: 2.07 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OFIX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.44 Max: 23.25
Current: 2.07
0.55
23.25
Price-to-Median-PS-Value 1.31
OFIX's Price-to-Median-PS-Value is ranked lower than
68% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. OFIX: 1.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OFIX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.22 Max: 2.98
Current: 1.31
0.33
2.98
Earnings Yield (Greenblatt) % 2.52
OFIX's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. OFIX: 2.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OFIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -62.8  Med: 2.95 Max: 16.9
Current: 2.52
-62.8
16.9
Forward Rate of Return (Yacktman) % 2.70
OFIX's Forward Rate of Return (Yacktman) % is ranked lower than
65% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 8.76 vs. OFIX: 2.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
OFIX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -41.7  Med: 3.8 Max: 32.6
Current: 2.7
-41.7
32.6

More Statistics

Revenue (TTM) (Mil) $413.85
EPS (TTM) $ -0.19
Beta0.35
Short Percentage of Float5.58%
52-Week Range $32.51 - 48.25
Shares Outstanding (Mil)18.04

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 410 414 426
EPS ($) 1.54 1.74 1.75
EPS without NRI ($) 1.54 1.74 1.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OFIX

Headlines

Articles On GuruFocus.com
Three Growing Companies Worth a Second Look Oct 09 2013 
Weekly CEO Buys Highlight: MOSY, PMT, APA, CUBI, OFIX May 26 2013 
Weekly 3-Year Low Highlights: SBY, PER, OFIX, EDG May 14 2013 
Orthofix International N.V. Reports Operating Results (10-K) Mar 03 2011 
Orthofix International N.V. (OFIX) CEO Alan Milinazzo buys 1,100 Shares Nov 09 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Oct 28 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Jul 29 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Apr 29 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Nov 06 2009 
Orthofix International N.V. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
ETFs with exposure to Orthofix International NV : June 19, 2017 Jun 19 2017
Orthofix International NV :OFIX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Orthofix to Present at Healthcare Conferences in June 2017 May 31 2017
Edited Transcript of OFIX earnings conference call or presentation 4-May-17 8:30pm GMT May 09 2017
Orthofix reports 1Q loss May 04 2017
Orthofix International Reports First Quarter 2017 Financial Results May 04 2017
Investor Network: Orthofix International NV to Host Earnings Call May 04 2017
Orthofix Introduces New Brand Identity for Extremity Fixation Pediatric Products May 01 2017
Orthofix International Schedules First Quarter 2017 Earnings Release and Conference Call for May 4,... Apr 25 2017
Not an inside job: How two analysts became SEC whistleblowers Apr 25 2017
Orthofix International NV – Value Analysis (NASDAQ:OFIX) : April 20, 2017 Apr 20 2017
Orthofix International NV breached its 50 day moving average in a Bullish Manner : OFIX-US : April... Apr 19 2017
Orthofix International NV breached its 50 day moving average in a Bearish Manner : OFIX-US : April... Apr 06 2017
6 Stocks Trading Up With Unusual Volume Mar 16 2017
Orthofix International (OFIX) Looks Good: Stock Jumps 9.9% Mar 15 2017
Orthofix International NV breached its 50 day moving average in a Bullish Manner : OFIX-US : March... Mar 15 2017
6 Stocks Trending Up With Major Volume Mar 15 2017
Synopsys Set to Join S&P 500; The GEO Group to Join S&P MidCap 400; Coca-Cola Bottling and Orthofix... Mar 13 2017
Orthofix International NV :OFIX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017 Mar 09 2017
Edited Transcript of OFIX earnings conference call or presentation 27-Feb-17 9:30pm GMT Feb 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}